Liftstream is an executive search recruitment company in the life sciences sector
Kuros Biosurgery Closes Round at CHF 20m
Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products and focused in therapeutic areas covering sealants and orthobiologics, today announces that it has raised an additional CHF 5 million in a fully subscribed second closing of its financing round. The CHF 5 million was raised from a group of non-disclosed new and existing investors and brings the total raised in the round to CHF 20 million.
Roche announces acquisition of InterMune
Authored by James Sheppard
Posted in Uncategorized
Tagged acquisition, Bay Area Cluster, bioValley, Boston Biotech, Genentech, IDF, idiopathic pulmonary fibrosis, InterMune, M&A, pirfenidone, Roche, Severin Schwan, Switzerland
Leave a comment
Novartis and Google collaborate to develop ‘Smart Contact Lenses’
Authored by James Sheppard
Novimmune sees immunotherapy and orphan focus attract new capital
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged acute lymphocytic leukemia, Alexion, Angel investment, Ariad, bioValley, Covagen, Crohn's disease, Dr Jonathan hepple, Geneva, Hemophagocytic lymphohistiocytosis, Lomard odier ventures, Merck Serono, monoclonoal antibody therapeutics, NovImmune, Nyon, Rare Disease, renal allograft transplantation, Rosetta Capital, Shire, Switzerland, Vertex Pharmaceuticals, Zug
Leave a comment
ADC Therapeutics executives on fast track with funding and partners
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC Therapeutics, Antibody-drug conjugates, AstraZeneca, Auven Therapeutics, bioValley, cancer, Cancer Research Technology, Celtic Therapeutics, Dr Patrick van Berkel, Genmab, haematological malignacies, HuMax-TAC, Laussane, M&A, MedImmune, Michael Forer, oncology, partnering, PBD Warheads, Rosetta Capital, solid tumor, Spirogen, Switzerland, VivaMab
Leave a comment
Shire expands rare disease reach with Viropharma Purchase
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged acquisition, Basingstoke, Cinryze, clinical development, EU, Flemming Ornskov, Geneva, immune disorder hereditary angioedema, Lotus Tissue Repair, marketed products, Pipeline, regulatory approval, restructure, SARcode, Shire, Shire HGT, Shire Rare Disease, Switzerland, USA, Viropharma, Zug
Leave a comment
Roche Returns to Antibiotics with Polyphor Deal
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged A*STAR, antibiotics, AstraZeneca, bacterial infection, CDC, Center for Disease Control & Prevention, clinical development, ETC and ETPL, gRED, Head of Infectious Diseases Discovery and Translational, hospital-acquired infection, infection, Infectious Disease, John Reed, macrocycle, partnering, Polyphor, pRED, Pseudomonas aeruginosa, Roche, Singapore, Switzerland, Tom Frieden
Leave a comment
PAH franchise and cost cutting prevent Actelion from listing further
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Actelion, cost cutting, dual endothelin receptor antagonist, Elliott Advisors, FDA, GSK, Jean-Paul Clozel, JP Garnier, Opsumit, Orphan drugs, PAH, pulmonary arterial hypertension, rare diseases, Switzerland, Tracleer
Leave a comment
Polyphor begin Board succession with appointment of pharmaceutical Senior Executives
Authored by Karl Simpson
Posted in Pharmaceutical business, Recruitment Market
Tagged Alpha Antitryspin Deficiency, bioValley, board appointment, board executives, Chairman, CXCR4 antagonist, Cystic Fibrosis, Jean-Jacques Garaud, Jerry Karabelas, neutrophil elastase, Novartis, oncology, Pharmacueticals, POL6326, POL7080, Polyphor, Research & Early development, Roche, Switzerland, Worldwide Pharmaceutical
Leave a comment
GSK Expands Vaccines Capabilities with Okairos Purchase
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Emmanuel Hannon, GSK, Hepatitis, HIV, M&A, merger, Okairos, oncology, purchase, Switzerland, technology, UK, vaccine, vaccines
Leave a comment